Recently, specific targeted therapies against mutant IDH have offered novel lines of therapy for AML patients (Lu et al., 2012; Wang et al., 2013; Kernytsky et al., 2015; Papaemmanuil et al., 2016; Xu et al., 2017; Olarte et al., 2019). This evidence concerns the gene IDH2 and acute myeloid leukemia.